Joel Greenblatt’s Summit Therapeutics SMMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$564K Buy
33,333
+17,606
+112% +$263K ﹤0.01% 1560
2026
Q2
$229K Hold
15,727
– – ﹤0.01% 1709
2026
Q1
$298K Hold
15,727
– – ﹤0.01% 1607
2025
Q4
$275K Hold
15,727
– – ﹤0.01% 1587
2025
Q3
$325K Sell
15,727
-2
-0% -$49 ﹤0.01% 1495
2025
Q2
$335K Sell
15,729
-56
-0.4% -$1.28K ﹤0.01% 1429
2025
Q1
$304K Hold
15,785
– – ﹤0.01% 1356
2024
Q4
$282K Sell
15,785
-123
-0.8% -$2.38K ﹤0.01% 1289
2024
Q3
$348K Sell
15,908
-3,592
-18% -$50.2K ﹤0.01% 1191
2024
Q2
$152K Buy
+19,500
New +$105K ﹤0.01% 1360

Other funds holding SMMT

Joel Greenblatt's SMMT Position: Q3 2026 in Review

Joel Greenblatt increased its Summit Therapeutics (SMMT) stake by 112% in Q3 2026, buying an estimated $263K and bringing the position to 33,333 shares worth $564K. The position accounts for ﹤0.01% of the portfolio, ranked #1560.

Joel Greenblatt first reported a position in SMMT in Q2 2024 and has held it in 10 quarters since. 298 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

  • Joel Greenblatt held 33,333 shares of Summit Therapeutics worth $564K as of Q3 2026.
  • Joel Greenblatt bought 17,606 Summit Therapeutics shares in Q3 2026, an estimated $263K.
  • Summit Therapeutics made up ﹤0.01% of Joel Greenblatt's portfolio in Q3 2026, its #1560 holding.
  • Joel Greenblatt first reported a position in Summit Therapeutics in Q2 2024 and has held it in 10 quarters since.
  • 298 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on Gotham Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.